Table 4 Overall situation of evidence support for the effectiveness of anti-hypertensive medicines in NRDL
| Â | Sound evidence support | Subtotal | Insufficient evidence support | Subtotal | ||||
|---|---|---|---|---|---|---|---|---|
Support from international evidence-based drug list | Support from systematic review or meta-analysis | Support from RCT | Reported by RCT with poor quality | No evidence involved | No definite conclusion in systematic review or meta-analysis | |||
Calcium antagonist | 7 (29.2%) | 6 (25.0%) | 1 (4.2%) | 14 (58.3%) | 0 (0.0%) | 7 (29.2%) | 3(12.5%) | 10 (41.7%) |
β blockers | 6 (42.9%) | 3 (21.4%) | 1 (7.1%) | 10 (71.4%) | 1 (7.1%) | 2 (14.3%) | 1 (7.1%) | 4 (28.6%) |
Diuretics | 4 (36.4%) | 0 (0.0%) | 2(18.2%) | 6 (54.6%) | 0 (0.0%) | 5 (45.4%) | 0 (0.0%) | 5 (45.4%) |
ACEIs | 3 (20.0%) | 4 (26.7%) | 4(26.7%) | 11 (73.3%) | 1 (6.7%) | 3 (20.0%) | 0 (0.0%) | 4 (26.7%) |
Angiotensin II receptor antagonist | 5 (41.7%) | 2 (16.6%) | 1 (8.3%) | 8 (66.7%) | 0 (0.0%) | 4 (33.3%) | 0 (0.0%) | 4 (33.3%) |
Vasodilators | 0 (0.0%) | 1 (14.3%) | 0 (0.0%) | 1 (14.3%) | 0 (0.0%) | 5 (71.4%) | 1 (14.3%) | 6 (85.7%) |
Others | 1 (7.1%) | 4 (28.6%) | 1 (7.1%) | 6 (42.9%) | 0 (0.0%) | 7 (50.0%) | 1 (7.1%) | 8 (57.1%) |
Class A | 13 (50.0%) | 4 (15.4%) | 1 (3.8%) | 18 (69.2%) | 1 (3.8%) | 6 (23.1%) | 1 (3.8%) | 8 (30.8%) |
Class B | 13 (18.3%) | 16 (22.6%) | 9 (12.7%) | 38 (53.5%) | 1 (1.4%) | 27 (38.1%) | 5 (7.0%) | 33 (46.5%) |
Total | 26 (26.8%) | 20 (20.6%) | 10 (10.3%) | 56 (57.7%) | 2 (2.1%) | 33 (34.0%) | 6 (6.2%) | 41 (42.3%) |